INTRODUCTION
Although there are few reliable estimates of the prevalence in use of herbal medicines (HM), 1 the market for HM continues to expand rapidly and has grown into a multibillion-dollar industry across the world. 2 The influence of religious, sociocultural, and socioeconomic issues, traditional practices, and belief in the use of HM is evident, particularly in Chinese, Indian, and African societies. Documented use of HM in Western societies is also high. 3, 4 Among consumers, there is widespread belief that remedies of natural origin are safe. Worldwide, most HM can be obtained without a prescription from various sources. The majority of HM are harmless in small doses 5 (derived chemicals of many plants are the basis of conventional drug therapies: eg, morphine/ Papaver somniferum L.; aspirin/Salix sp.; digoxin/Digitalis).
As with all medicines, however, HM have been shown to have adverse effects, which are related to a variety of causes, including adulteration, mistaken use of the wrong species or misidentification, incorrect dosing, errors in use, contamination (toxic metal, microbes, microbial toxins, environmental pollutants), and toxic constituents (for example, aristolochic acids, nephrotoxins found in Aristolochia species). HM affect pharmacokinetic and pharmacodynamic properties of conventional drugs and thus cause herb-drug interactions. 6 Unfortunately, clinicians and consumers do not always have information that permits robust inferences about interactions between HM and prescribed drugs.
HM chemical constituents responsible for pharmacological activity are many and complex, and the majority of them have not been identified. Distribution of constituents is not uniform throughout a plant. So, depending on the plant part used medicinally, chemical constituents could vary both qualitatively and quantitatively. For the same plant part, constituents vary in relation to other factors such as intraspecies and interspecies variation in components, climate, harvesting, drying, storage and transport conditions, preparation method and method of extraction. On the other hand, HM are usually used as mixtures of two or more plants with different herbal ingredients specific to each one. In addition to the chemical complexity of HM, many patients take these ''natural'' products concomitantly with drugs prescribed by their physicians.
For these reasons, there is a major difficulty in determining the clinical pharmacokinetic and pharmacodynamic effects when HM are implicated. There is no doubt that there is potential for HM to interact adversely with prescription medicines, with danger of injury and even death. There are no government standards for the quality of HM in most countries, and the main problem is that little is known about them scientifically. Furthermore, HM are not tested with the scientific rigor required of conventional drugs. The absence of a regulatory framework presents the major problem in pharmacovigilance for HM.
This article highlights the evidence on herb-drug interactions from a systematic literature search using electronic databases and manual searches from 1966 to 2006. A further goal is to discuss the particular challenges in this field and to make recommendations to encourage the necessary clinical trials on HM and herb-drug interactions.
For the purpose of this article, the term HM means unconventional or alternative therapies and includes herbs, herbal materials, herbal preparations supplied by herbalists, and finished or manufactured herbal products found in pharmaceutical dosage forms (tablets, capsules), as defined by the World Health Organization.
MATERIALS AND METHODS
The search for literature data involved a variety of electronic databases: Medline via PubMed, Allied and Complementary Medicine Database, HealthSTAR, AMBASE, CINHAL, Cochrane Library, Internet documents, and manually searched references (WHO documents and books available in Moroccan Pharmacovigilance Centre). The review used the search terms herbal medicines, phytotherapy, herbdrug and/or herb-herb interactions, adverse effects, herbal medicines and prescribed drugs, self-medication, herbal medicines and pregnancy period, and pharmacokinetic and pharmacodynamic drug interactions. They were searched in sources from 1966 to 2006. This involved all articles written with a focus on the risk of herb-drug interactions and potential side effects with herbal medicines, regardless of whether they were based on case reports, clinical trials, or other types of investigation in humans. There was no language restriction for literature searches. In vitro experiments were excluded. All data were extracted, fully read, and validated by the first author. One-hundred thirty articles were identified; 103 of them were retained, of which 62% concerned full text and 38% were abstract data. This article was written by the first author and validated by the second and third authors (see footnote to title page).
RESULTS AND DISCUSSION
Because HM use has grown significantly, it is important to investigate the potential impact of herb-drug interactions on patient safety and to contribute to public and scientific debate on this matter. The potential risks resulting from such interactions have received attention in several reviews and are subject to much current interest, [8] [9] [10] [11] but updated information in the absence of rigorous studies to assess the clinical significance of herb-drug interactions is still needed to guide practitioners involved in patient care.
Herbal medicines are used to treat many different ailments, from common to serious and from acute to chronic, such as diabetes, hypertension, rheumatism, cancer, asthma and AIDS. Herb-drug interactions may occur in many situations, even when herbal medicines are used for weightreduction, performance and energy enhancement, or bodybuilding. An example is seen with the alkaloids obtained from species of Ephedra (Ephedraceae), administered as herbal medicines or as products containing synthetically prepared ephedrine and pseudoephedrine. The alkaloids, via catecholamines, can cause adverse cardiovascular events associated with arrhythmias, palpitations, tachycardia, myocardial infarction, and death. 12, 13 Ephedrine raises blood pressure and induces peripheral vasoconstriction. Consumption of caffeine in Coffea arabica L. (Rubiaceae) or present in the same HM or in drugs, and in association with ephedrine, increases the cardiovascular risk. 14, 15 The danger of using ephedrinecontaining products is higher in patients who are sensitive to the effects of sympathomimetic agents (ie, patients with hypertension, hyperthyroidism, diabetes mellitus, psychiatric conditions, glaucoma, prostate enlargement, seizure disorders, and cardiovascular disease). 16 In general, interactions between herbal medicines and other medicines are associated more with specific categories of HM than others, the quality of the HM, the drug class, the pathology and the patient population. [17] [18] [19] [20] Many herb-drug interaction case reports can be found in the literature. 21 For example: St. John's wort (Hypericum perforatum L., Hypericaceae) with its main constituents of hypericin, hyperforin, and flavonoids, is one of the most commonly used HM for the treatment of mild to moderate depression in Western countries. It may have an important influence on the effectiveness, safety, and outcome of a range of drug therapies. This is the case in relation to serotonin reuptake inhibitors and warfarin. 22, 23 In the latter case, St. John's wort decreases the anticoagulant effect when taken with warfarin. The possible mechanism is hepatic enzyme induction, and there is evidence to suggest this. Warfarin is metabolized by CYP 1A2 in the liver, which is induced by St. John's wort 24 ; St. John's wort and induction of the human cytochrome P450 enzymes CYP 3A4, CYP2C9, and CYP1A2. [25] [26] [27] [28] [29] St. John's wort and cyclosporine coadministration after organ transplantation may result in cyclosporine therapeutic failure in transplant graft rejection, 28, 30 and St. John's wort can increase the expression of P-glycoprotein, with potential drug interactions.
31-33 P-glycoprotein is vulnerable to inhibition, activation, or induction by certain HM. 20, 34 Several herbs containing curcumin, piperine, and catechins have an effect on P-glycoprotein-mediated drug transport. 32 Other examples of potential interactions include those with Panax ginseng species (Araliaceae) and plant flavonoids. In the case of ginseng, it appears to decrease the anticoagulant effect of warfarin, resulting in thrombotic complications, 23, 24, [35] [36] [37] [38] but the mechanism is not reported in the literature. Matricaria chamomilla (Asteraceae) appears to have the same interaction as ginseng with warfarin, with respect to the coumarin constituent of this plant. 37, 39 Interaction between ginseng and phenelzine or alcohol is also reported. 35 In patients treated with phenelzine, ginseng may cause headache, trembling, and manic behavior. 40 Plant flavonoids, including isoflavones, are natural components of many plant phenolics and drug-metabolizing enzymes. 41 Despite their common use, it is not widely recognized that HM can alter the efficacy of coadministered prescription drugs. Table 1 summarizes more examples of common herbdrug interactions.
T1
The evidence from the literature that HM have pharmacological effects and may lead to adverse interactions when coadministered with prescription medicines has grown AU1 . [42] [43] [44] However, there is not enough information or adequate analysis to estimate the magnitude of the problem. 46, 47 Pharmacokinetic and pharmacodynamic mechanisms account for herbdrug interactions. HM may affect absorption, metabolism, distribution, and excretion mechanisms. A pharmacokinetic interaction occurs in general when drugs (drug-drug; herbaldrug; and herbal-herbal) are coadministered, and one drug affects the metabolism of the other drug by inhibition or induction of the specific CYP enzymes involved in its metabolism. 48, 49 When HM are coadministered with prescription drugs, there may be induction or inhibition of drugmetabolizing enzymes. Altered drug protein binding and altered drug excretion may also happen, although the degree of [50] [51] [52] This large family of enzymes has been shown to be involved in interactions between drugs and herbs. Pharmacokinetic interactions often occur as a result of changes in activity of drug-metabolizing and transporting proteins: cytochrome P450 isoenzymes and P-glycoprotein. 53 Herbal medicines, when coadministered with prescription medicines, either induce or inhibit CYP enzymes. 54, 55 This is exemplified by aristolochic acids contained in Aristolochia species plants undergoing reduction of the nitro group by hepatic cytochrome P450. 56 Use of HM and a prescription drug has the potential to decrease or increase the effect of the drug. 57 Eleutherococcus senticosus Rupt. & Maxim (Araliaceae), for example, increased the serum concentration of digoxin. 58 However, pharmacological and clinical data are lacking on the majority of herbal products. 59 Interactions may occur between different HM themselves. Many examples have been reported. One of these concerns fenugreek (Trigonella foenum-graecum L., Fabaceae), which may lower blood sugar levels, [60] [61] [62] and when it is used with other herbs that may alter blood sugar levels, such as Momordica charantia L. (Cucurbitaceae), dose adjustments may be necessary. Fenugreek may also increase the risk of bleeding when taken with Ginkgo biloba L. (Ginkgoacea) or Allium sativum L. (Alliaceae).
It is particularly important to be cautious when taking HM in certain circumstances, such as when the risk of adverse events and interactions is great and for some categories of patients who may potentially be more vulnerable to such interactions. During pregnancy and breast-feeding, surveys show, 36% to 45% of pregnant women use herbal remedies 20, 63 ; this is probably in the mistaken belief that HM as natural products are safer than chemical drugs. This new thinking also applies to the use of HM in children. Women consider herbs taken during gestation or breast-feeding less dangerous than drugs. [64] [65] [66] Few studies have assessed the use of HM in pregnancy and the factors related to this use. Herbs are taken for venous insufficiency, lactation, gastroesophageal reflux, constipation, depression, and cutaneous problems and as caffeine substitutes. Also, HM may be taken for more serious disorders, particularly during the first trimester of pregnancy. Unfortunately, women ignore that this is the most sensitive period for serious adverse reactions and events.
In patients who are undergoing anticoagulant pharmacotherapy, HM may interact with cardiovascular drugs. 21 Warfarin is the most common drug involved. Herbs such as fenugreek and Ferula communis L. can increase the risk of bleeding (resulting in over-anticoagulation) when combined with warfarin, heparin, and other anticoagulants, due to the presence of coumarins. 67 A case involving giant fennel has been reported to the Moroccan Pharmacovigilance Centre. Ginkgo biloba L. has been reported to cause spontaneous bleeding, and it may interact also with anticoagulants and antiplatelet agents. 16 The risk appears to be higher among patients on chronic anticoagulation therapy.
Another circumstance is when HM are used in the preoperative period or in the context of anesthesia. In this period, several drugs may be administered within a short period of time and anesthetists may not be aware that their patients are taking HM. The use of herbal medications among presurgical patients may have a negative impact on perioperative patient care. 68 Indeed, herbal remedies such as Allium sativum L., Panax species, Ginkgo biloba L., Hypericum perforatum L., and Valeriana officinalis L. (Valerianaceae) can interact with drugs and lead to many complications such as prolonged or inadequate anesthesia, when they are taken in the preoperative period. 69, 70 This is probably caused by the modulation of gamma-aminobutyric acid (GABA) neurotransmission. [71] [72] [73] [74] In this same period, Zingiber officinale Roscoe (Zingiberaceae) and Aloe vera (Liliaceae) do not prevent postoperative nausea and vomiting, as perceived by some patients. 75, 76 Another example is the use of Piper methysticum Forst.f. (Piperaceae) in the perioperative period: the consumption of this herbal remedy (with anxiolytic and sedative properties) has potential cardiovascular effects that could manifest in the perioperative period. Kava seems to act through inhibition of sodium and calcium channels to conduct direct decreases in systemic vascular resistance and blood pressure. However, no explanation of a mechanism for this effect has emerged from the literature. Kava may also produce adverse neurologic effects (possibly related to its dopaminergic antagonism) 77, 78 that may cause excessive perioperative sedation. 79 The pharmacokinetic and pharmacodynamic aspects of such interactions with this plant have not been studied systematically. However, pharmacodynamic herbdrug interactions include potentiation of the sedative effect of anesthetics by kava. On the other hand, kavalactones, the active component of kava extracts, have potential as inhibitors of several enzymes of the CYP 450 system. 80 So kava has the potential to interact with all drugs, even herbal products, which are metabolized by the CYP 450 enzymes. Other side effects such as coagulopathies, water and electrolyte disturbances, endocrine effects, and hepatotoxicity were observed, in relation with HM consumption. 81 Among cancer patients, garlic, ginkgo, echinacea (Asteraceae), ginseng, St. John's wort, and kava have been reported as natural products that can cause potential pharmacokinetic interactions with anticancer drugs. 82 HM-anticancer drug interactions can occur at the pharmaceutical, pharmacodynamic, or pharmacokinetic level. 83 Pharmacokinetic interactions are the most likely. They involve changes in absorption, distribution, metabolism, and excretion of the chemotherapeutic drug. It is estimated that HM-anticancer drug interactions are responsible for possible undertreatment seen in cancer patients. Induction of drug-metabolizing enzymes leads to therapeutic failure with lower plasma levels of the anticancer drugs. ATPbinding cassette drug transporters are also involved in HManticancer drug interactions and can be one of the mechanisms behind these interactions. Nuclear receptor (pregnane X receptor, the constitutive androstane receptor, and the vitamin D-binding receptor were recently identified) plays an important role in the induction of metabolizing enzymes and drug transporters. Kava-kava, ginseng, garlic and echinacea are already implicated in these purposes. 81 In patients who use multiple medications, particularly elderly patients, 84 ,85 polypharmacy and self-medication increase the possibilities of herb-drug interactions. 86 Because of their presumed harmlessness, HM are often taken by patients with chronic illness, [87] [88] [89] along with added medication prescribed by physicians, and then are taken chronically. Use of both medicines simultaneously has a higher potential for producing adverse events. In some situations, symptoms of disease or treatment are similar to those associated with HM adverse effects, and it is difficult to identify the problem. 87 This could have an influence on quality of treatment. Finally, some patients use crude forms of HM; in many developing countries the source and quality of the medicines is unknown. HM are in common use and available in street markets. Risks of interaction increase with the variability in packaging and labeling (eg, information on plant species, part of the plant utilized, type of preparation, type of marker compound). The information for commercial herbal products may not always be complete, when HM may often contain a combination of ingredients, some unknown, and of unregulated quality.
Recommendations
The concurrent use of HM with prescribed drugs must take into account their safety, efficacy, consistency, and quality. [90] [91] [92] [93] The safety of HM requires strict control of the presence of adulterants, the dosage labeling, contraindications, manufacturing techniques, and a list of all ingredients. There is often no requirement to list each ingredient of every herbal preparation on the label; more significantly, only some of the ingredients are listed, but not others that may be potentially harmful. Unfortunately, there is also no requirement to precisely state the dose of active ingredients contained in herbal preparations. This should be ensured through pharmacovigilance processes and strict regulatory controls. 94, 95 There is a need for an adequate regulatory framework for herbal products to effectively protect consumers and patients. The clinical importance of herb-drug interactions depends on many factors associated with the particular herb, drug, and patient. HM should be appropriately labeled to alert consumers to potential interactions when concomitantly used with drugs. The widespread use of HM in pregnancy and during the breast-feeding period indicates an increased need for documentation about their safety and efficacy. Unfortunately, both the efficacy and safety data are largely lacking for the majority of HM, so they can not be recommended during pregnancy and lactation. Patients with cancer should avoid HM that may complicate their cancer care. During the preoperative evaluation, physicians should be familiar with the potential preoperative effects of the commonly used herbal medications, in order to prevent, recognize, and treat potentially serious problems associated with their use. It is important for health professionals, consumers, and other interested stakeholder groups, including regulatory authorities and suppliers of HM, to be aware of the side effects and drug interactions caused when herbal medicines are administered with conventional drugs. Patients should disclose their use of herbal medicines to their physicians and pharmacists, who then will be aware of potential herb-drug interactions. More effective communication between all these partners is needed, and information must be accessible to all, 96 which means that the responsibility of the safety information is shared. Various methods can be considered for all relevant target audiences, such as involvement of the mass media and patient/consumer associations (including translation into local languages where appropriate and essential for the public at large); education of health professionals via the delivery of adverse-reaction bulletins or articles and meetings; and education about the implications for HM providers, academics, researchers/scientists, and the pharmaceutical and herbal medicine industries. Communication must be an inclusive network, well structured, collaborative, and adapted to the local and cultural situation. It is imperative that physicians are aware of all medications, both conventional and HM, that their patients are taking, in order to provide the best care. This should be possible by direct patient questioning. Physicians must regularly ask their patients about their use of HM, particularly elderly patients 85 and those whose disease is not responding to treatment as expected. This is important because adverse reactions observed following use of conventional medicines might in reality be due to HM or herb-drug interactions, when physicians and other healthcare providers are unaware of the extent of a patient's self medication with alternative therapies. 97 Herb-drug interactions must be monitored. Scientific recommendations on the use of HM and their coadministration with conventional therapy should be based on robust scientific data rather than on the inadequate data of case reports only. A thorough evaluation of the interaction of HM with other medicines should be carried out; little attention has been paid to this issue to date. Current literature data are unsubstantiated, with conclusions based on single or limited reports. These data are generally insufficient to predict the incidence of herb-drug interactions. Thus, herb-drug interactions !need to be investigated through greater research, particularly by meta-analysis of prospective and clinical studies using large population samples in order to avoid the problems with individual susceptibility 98 Prospective randomized clinical trials assessing herb-drug interactions is an urgent need. Exchange of data and research results among countries must be encouraged and supported by improvement in international conventions. Funds available for scientific and medical research should also be directed into clinical trials of HM. The inclusion of information on HM as a source of therapy will be needed in our academic programs. Pharmacological aspects of phytotherapy should be included in the regular medical and pharmacy curriculum 99 Listing of safe combinations of HM and conventional drugs can be provided as a guide to patient cares 100 
CONCLUSION
Crude drugs and finished herbal products are often marketed as herbal medicines or dietary supplements for their claimed therapeutic effects and miraculous cures. Unfortunately, HM are not free of risk and interactions between these products and prescription medications are an increasing concern and may have significant public consequences. However, in most cases the claims have not been substantiated and few HM have been subjected to double-blind, randomized, placebo-controlled clinical trials. Their potential to cause adverse effects and interaction with conventional drugs are an understudied field of research. It is important to be aware that most HM fall outside of the regulatory framework and evidence is generally lacking on their safety, efficacy or standards of manufacture and control. Until now, herbal medications were lawfully ignored or classified as dietary supplements. This exempts many herbal medications from safety and efficacy requirements and regulation. On the other hand, more research and information are required (eg, preclinical, animal studies, premarketing controlled clinical trials, or postmarketing surveillance) in order to guarantee the safety of patients using HM.
